Vecchione L, Jacobs B, Normanno N, Ciardiello F, Tejpar S: EGFR-targeted therapy. Exp Cell Res. 2011, 317 (19): 2765-71. 10.1016/j.yexcr.2011.08.021.
Article
CAS
PubMed
Google Scholar
Seshacharyulu P, Ponnusamy MP, Haridas D, Jain M, Ganti AK, Batra SK: Targeting the EGFR signaling pathway in cancer therapy. Expert Opin Ther Targets. 2012, 16 (1): 15-31. 10.1517/14728222.2011.648617.
Article
CAS
PubMed
PubMed Central
Google Scholar
Vallbohmer D, Lenz HJ: Epidermal growth factor receptor as a target for chemotherapy. Clin Colorectal Cancer. 2005, 5 (Suppl 1): S19-27.
Article
CAS
PubMed
Google Scholar
Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004, 351 (4): 337-45. 10.1056/NEJMoa033025.
Article
CAS
PubMed
Google Scholar
Mendelsohn J, Baselga J: The EGF receptor family as targets for cancer therapy. Oncogene. 2000, 19 (56): 6550-65. 10.1038/sj.onc.1204082.
Article
CAS
PubMed
Google Scholar
Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoutian H, Amellal N, Rowinsky EK, Ang KK: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006, 354: 567-578. 10.1056/NEJMoa053422.
Article
CAS
PubMed
Google Scholar
Bernier J, Schneider D: Cetuximab combined with radiotherapy: an alternative to chemoradiotherapy for patients with locally advanced squamous cell carcinomas of the head and neck?. Eur J Cancer. 2007, 43: 35-45. 10.1016/j.ejca.2006.08.035.
Article
CAS
PubMed
Google Scholar
Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu J, Youssoufian H, Rowinsky EK, Ang KK: Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010, 11: 21-28. 10.1016/S1470-2045(09)70311-0.
Article
CAS
PubMed
Google Scholar
Numico G, Silvestris N, Grazioso RE: Advances in EGFR-directed therapy in head and neck cancer. Front Biosci (Schol Ed). 2011, 3: 454-66. 10.2741/s164.
Article
Google Scholar
Hello M, Barbarot S, Connault J: Skin manifestations of new targeted treatments. Rev Med Interne. 2012, 33 (5): 273-8. 10.1016/j.revmed.2012.01.013.
Article
CAS
PubMed
Google Scholar
Li T, Perez-Soler R: Skin toxicities associated with epidermal growth factor receptor inhibitors. Target Oncol. 2009, 4 (2): 107-19. 10.1007/s11523-009-0114-0.
Article
PubMed
Google Scholar
Hu JC, Sadeghi P, Pinter-Brown LC, Yashar S, Chiu MW: Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management. J Am Acad Dermatol. 2007, 56 (2): 317-26. 10.1016/j.jaad.2006.09.005.
Article
PubMed
Google Scholar
Balagula Y, Garbe C, Myskowski PL, Hauschild A, Rapoport BL, Boers-Doets CB, Lacouture ME: Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors. Int J Dermatol. 2011, 50 (2): 129-46.
Article
CAS
PubMed
Google Scholar
Gutzmer R, Becker JC, Enk A, Garbe C, Hauschild A, Leverkus M, Reimer G, Treudler R, Tsianakas A, Ulrich C, Wollenberg A, Homey B: Management of cutaneous side effects of EGFR inhibitors: recommendations from a German expert panel for the primary treating physician. J Dtsch Dermatol Ges. 2011, 9 (3): 195-203.
PubMed
Google Scholar
Potthoff K, Hassel J, Wollenberg A, Hofheinz R: Therapie und Prophylaxe EGFR Inhibitor induzierter Hautreaktionen. Arzneimitteltherapie. 2010, 28: 191-198.
CAS
Google Scholar
Potthoff K, Hofheinz R, Hassel JC, Volkenandt M, Lordick F, Hartmann JT, Karthaus M, Riess H, Lipp HP, Hauschild A, Trarbach T, Wollenberg A: Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion. Ann Oncol. 2011, 22 (3): 524-35. 10.1093/annonc/mdq387.
Article
CAS
PubMed
Google Scholar
Lacouture ME, Anadkat MJ, Bensadoun R-J, Bryce J, Chan A, Epstein JB, Eaby-Sandy B, Murphy BA: Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Supportive Care in Cancer. 2011, 19 (8): 1079-1095. 10.1007/s00520-011-1197-6.
Article
PubMed
PubMed Central
Google Scholar
Wollenberg A, Kroth J, Hauschild A, Dirschka T: Cutaneous side effects of EGFR inhibitors—appearance and management. Dtsch Med Wochenschr. 2010, 135 (4): 149-154. 10.1055/s-0029-1244831.
Article
CAS
PubMed
Google Scholar
Segaert S, Van Cutsem E: Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol. 2005, 16: 1425-1433. 10.1093/annonc/mdi279.
Article
CAS
PubMed
Google Scholar
Segaert S, Tabernero J, Chosidow O, Dirschka T, Elsner J, Mancini L, Maughan T, Morere JF, Santoro A, Sobrero A, Van Cutsem E, Layton A: The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies. J Dtsch Dermatol Ges. 2005, 3 (8): 599-606. 10.1111/j.1610-0387.2005.05058.x.
Article
PubMed
Google Scholar
Katzer K, Tietze J, Klein E, Heinemann V, Ruzicka T, Wollenberg A: Topical therapy with nadifloxacin cream and prednicarbate cream improves acneiform eruptions caused by the EGFR-inhibitor cetuximab - A report of 29 patients. Eur J Dermatol. 2010, 20 (1): 82-4.
CAS
PubMed
Google Scholar
Jatoi A, Rowland K, Sloan JA, Gross HM, Fishkin PA, Kahanic SP, Novotny PJ, Schaefer PL, Johnson DB, Tschetter LK, Loprinzi CL: Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB). Cancer. 2008, 113 (4): 847-53. 10.1002/cncr.23621.
Article
CAS
PubMed
PubMed Central
Google Scholar
Ocvirk J, Rebersek M: Managing cutaneous side effects with K1 vitamin creme reduces cutaneous toxicities induced by cetuximab. J Clin Oncol. 2008, 26: abstract 20750
Google Scholar
Melosky B, Burkes R, Rayson D, Alcindor T, Shear N, Lacouture M: Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations. Curr Oncol. 2009, 16: 16-26.
Article
CAS
PubMed
PubMed Central
Google Scholar
Common Terminology Criteria for Adverse Events v4.02 (CTCAE). http://evs.nci.nih.gov/ftp1/CTCAE/Archive/CTCAE_4.02_2009-09-15_QuickReference_5x7_Locked.pdf (6 Sept 2012, date last accessed)
Burtness B, Anadkat M, Basti S, Hughes M, Lacouture ME, McClure JS, Myskowski PL, Paul J, Perlis CS, Saltz L, Spencer S: NCCN Task Force Report: management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer. J Natl Compr Canc. 2009, 7 (S1): s5-s21.
Google Scholar
Aygenc E, Celikkanat S, Kaymakci M, Aksaray F, Ozdem C: Prophylactic effect of pentoxifylline on radiotherapy complications: a clinical study. Otolaryngol Head Neck Surg. 2004, 130: 351-356. 10.1016/j.otohns.2003.08.015.
Article
PubMed
Google Scholar
Shah NT, Kris MG, Pao W, Tyson LB, Pizzo BM, Heinemann MH, Ben-Porat L, Sachs DL, Heelan RT, Miller VA: Practical management of patients with non-small-cell lung cancer treated with gefitinib. J Clin Oncol. 2005, 23 (1): 165-174. 10.1200/JCO.2005.04.057.
Article
CAS
PubMed
Google Scholar
Suppan C, Herrmann C, Jäger D, Herrmann T: ECA – Verbesserte Lebensqualität durch Behandlung EGFR-AK-bedingter Rhagaden mit Ethyl-2-Cyanoacrylat. Onkologie. 2010, 33 (S2): 1-228.
Google Scholar
Habl G, Potthoff K, Haefner MF, Abdollahi A, Hassel JC, Boller E, Indorf M, Debus J: Differentiation of irradiation and cetuximab induced skin reactions in patients with locally advanced head and neck cancer undergoing radioimmunotherapy: the HICARE protocol (head and neck cancer: immunochemo- and radiotherapy with erbitux) - a multicenter phase IV trial. BMC Cancer. 2013, 13: 345-353. 10.1186/1471-2407-13-345.
Article
CAS
PubMed
PubMed Central
Google Scholar